by Mark Chiang

由马克·蒋

Share To

分享到

Sanofi will present new data from 18 abstracts, including five oral presentations, at the 33rd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Washington D.C., scheduled to take place from June 21 to 25, 2025. The findings focus on advancements in treatments for rare blood disorders, with key highlights including research on rilzabrutinib’s potential in addressing immune dysregulation associated with immune thrombocytopenia (ITP).

赛诺菲将在2025年6月21日至25日于华盛顿特区举行的第33届国际血栓与止血学会（ISTH）大会上，展示来自18项摘要的新数据，其中包括五场口头报告。这些研究发现聚焦于罕见血液疾病治疗的进展，重点包括关于rilzabrutinib在应对与免疫性血小板减少症（ITP）相关的免疫失调中的潜力的研究。

Additional data will showcase developments related to hemophilia treatments ALTUVIIIO and Qfitlia, which aim to expand therapeutic options for patients..

更多数据将展示与血友病治疗药物ALTUVIIIO和Qfitlia相关的发展，这些药物旨在为患者扩展治疗选择。

The presented data emphasize Sanofi’s ongoing efforts in rare disease innovation. Rilzabrutinib is being studied for its ability to target underlying immune dysfunction in ITP, a condition characterized by low platelet counts due to autoimmune activity. Meanwhile, ALTUVIIIO and Qfitlia represent advancements in hemophilia care, offering potential improvements in treatment efficacy and patient outcomes.

所提供的数据强调了赛诺菲在罕见病创新方面的持续努力。Rilzabrutinib正被研究用于针对免疫性血小板减少症（ITP）中潜在的免疫功能障碍，这种疾病的特点是由于自身免疫活动导致的血小板计数低下。同时，ALTUVIIIO和Qfitlia代表了血友病治疗的进步，有望提高治疗效果并改善患者预后。

These findings underscore continued exploration into therapies designed to address unmet needs within the field of hematology..

这些发现强调了继续探索旨在解决血液学领域未满足需求的疗法。

Newsflash | Powered by GeneOnline AI

新闻快讯 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

来源：GO-AI-ne1

Date: June 6, 2025

日期：2025年6月6日

Related posts:

相关文章：

AI and 3D Printing Boost Generic Drug Development, Expanding Formulation Possibilities

人工智能和3D打印推动仿制药开发，拓展配方可能性

STAT’s D.C. Diagnosis Newsletter Delivers Twice-Weekly Health Policy Insights

STAT的华盛顿诊断通讯提供每周两次的健康政策洞察。

Teenage years crucial for depression intervention, study finds

研究发现，青少年时期是抑郁症干预的关键时期

Eli Lilly Secures Global Rights to Develop Long-Acting Therapies Using Camurus’ FluidCrystal Technology

礼来公司获得使用Camurus的FluidCrystal技术开发长效疗法的全球权利

©www.geneonline.com All rights reserved. Collaborate with us:

©www.geneonline.com 版权所有。与我们合作：

[email protected]

[email protected]

Author

作者

Mark Chiang

蒋志光

Related Post

相关文章

News Flash

新闻快讯

FDA Launches AI Initiative to Streamline Drug Reviews as Novo Nordisk Faces Rising Competition in Obesity Treatments

FDA启动人工智能计划以简化药物审查，而诺和诺德在肥胖症治疗领域面临日益激烈的竞争。

2025-06-11

2025年6月11日